Abstract
We aimed to demonstrate a single institution experience of treatment of pancreatic ductal carcinoma and to identify the role of radiation therapy. We assessed all patients who were diagnosed with pancreatic ductal carcinoma from January 2011 to December 2017. A total of 342 patients were enrolled. Thirteen, 131, 36, and 162 patients had stage I, II, III, and IV disease, respectively (UICC TNM, 7th edition). Among the patients with stages I–III disease, 94 underwent surgery, and the median overall survival (OS) was 33 months. Of patients with stages I–III disease who were not suitable for surgery, 58 patients received chemotherapy, and the median OS was 12 months. Among them, 17 patients received chemoradiotherapy added on chemotherapy and their OS was significantly better than that of patients who received chemotherapy alone. Of patients with stage IV disease, 111 received chemotherapy, and the median OS was 6 months. This study evaluated the demand, role, and outcome of each treatment modality and demonstrated a single institution experience of treatment of pancreatic ductal carcinoma. The demand and role of radiation therapy remained small; however, radiation therapy might have some importance as a local treatment.
Highlights
Pancreatic cancer is the fourth leading cause of cancer-related mortality in Japan
We aimed to identify the demand, role, and outcome of each treatment modality and demonstrate a single institution experience of treatment of pancreatic ductal carcinoma to understand the actual status
Those who were pathologically or clinically diagnosed with pancreatic ductal carcinoma were included in the analysis
Summary
Pancreatic cancer is the fourth leading cause of cancer-related mortality in Japan. An estimated 34,200 deaths occurred in Japan in 2017 [1]. The high biologically malignant nature of pancreatic cancer facilitates infiltration into the surrounding tissues and distant metastasis. Surgical resection is a treatment with the potential for cure; only
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
